## BAX: Baxter International Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -3.2% below STRENGTH zone (4.0-10.0%); PEG 35.01 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($17.00)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. BAX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Baxter International, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!**
- Source: WLNS 6 News | 20251207T120841 | Neutral | Relevance: 99%
-  Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Baxter International, Inc. (NYSE:BAX) and its officers. The lawsuit seeks damages for alleged violations of federal securities laws, citing systemic defects in Baxter's Novum LVP (Large Volume Pump) that allegedly caused widespread malfunctions and patient harm. Shareholders who purchased Baxter securities between February 23, 2022, and October 29, 2025, are encouraged to join the lawsuit, with a deadline of December 15, 2025, to request to be appointed as lead plaintiff.

**2. Pomerantz LLP Notifies Shareholders of Class Action Filing Against Baxter International, Inc. – BAX**
- Source: WATE 6 On Your Side | 20251208T120811 | Neutral | Relevance: 99%
-  Pomerantz LLP has announced a class action lawsuit against Baxter International, Inc. (NYSE: BAX) for alleged securities fraud. The lawsuit stems from Baxter's voluntary and temporary pause of shipments and installations of its Novum LVP medical device, which caused a significant drop in its stock price. Shareholders who purchased Baxter securities during the Class Period have until December 15, 2025, to seek appointment as Lead Plaintiff.

**3. Pomerantz LLP Notifies Shareholders of Class Action Against Baxter International, Inc. – BAX**
- Source: Fox 59 | 20251207T110000 | Neutral | Relevance: 99%
-  Pomerantz LLP has announced a class action lawsuit against Baxter International, Inc. (NYSE: BAX) following a significant drop in its stock price. The lawsuit stems from Baxter's "voluntary and temporarily pause" of shipments and installations of its Novum LVP medical device, which the company announced on July 31, 2025. Investors who purchased Baxter securities during the Class Period have until December 15, 2025, to seek appointment as Lead Plaintiff.

**4. Shareholders that lost money on Baxter International, Inc.(BAX) should contact The Gross Law Firm about pending Class Action - BAX**
- Source: CBS 42 | 20251209T011344 | Neutral | Relevance: 99%
-  The Gross Law Firm has issued a notice to shareholders of Baxter International, Inc. (NYSE: BAX) regarding a pending class action lawsuit. Shareholders who purchased BAX shares between February 23, 2022, and July 30, 2025, are encouraged to contact the firm, as the complaint alleges the company made materially false and/or misleading statements concerning systemic defects in its Novum LVP product. The deadline to seek lead plaintiff appointment is December 15, 2025.

**5. Securities Fraud Class Action Filed Against Baxter International, Inc. (BAX) - Levi & Korsinsky Reminds Investors of December 15, 2025**
- Source: WRIC ABC 8News | 20251207T210826 | Neutral | Relevance: 99%
-  Levi & Korsinsky, LLP has filed a securities fraud class action lawsuit against Baxter International, Inc. (NYSE: BAX) on behalf of investors who suffered losses due to alleged misrepresentations regarding the company's Novum LVP product. The lawsuit claims Baxter concealed systemic defects in the product that caused malfunctions and exposed patients to serious risks. Investors affected between February 23, 2022, and July 30, 2025, are encouraged to learn about their rights.

### Analyst Activity

**Target Signal:** VERY_BEARISH (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $15 | $19 | -21% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.16M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 65.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 15.1% (+14.9%)
- Vanguard Group Inc: 12.2% (+0.5%)
- Dodge & Cox Inc.: 11.2% (+10.1%)
- Pzena Investment Man: 11.2% (+45.9%)
- State Street Corpora: 4.3% (+0.3%)

### Key Risks

1. Valuation stretched: PEG 35.0x requires aggressive growth execution.
2. Elevated short interest (8.6%): bears positioning against stock.
3. Long-term trend broken: trading 32.5% below SMA200.
4. Falling knife pattern: rapid decline without stabilization, catch risk elevated.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 35.01 signals overvaluation risk, limited margin of safety. Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.3B |
| Beta | 0.61 |
| 52W Range | $17.40 - $37.74 |
| Short Interest | 8.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 35.01 |
| Forward P/E | 7.9 |
| Current P/E | 7.7 |
| YoY Growth | -2.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 1.3% to -3.2% (-4.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.2pp (needs >4.0% for momentum thesis). Below SMA200 (0.68x), long-term trend not supportive.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.21% (CS: 30) | Weak |
| RSI_14 | 39.6 | Neutral |
| MACD Histogram | 0.16 | Bullish |
| vs SMA20 | 0.988x | Below |
| vs SMA50 | 0.889x | Below |
| vs SMA200 | 0.675x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $18.16
- **Stop Loss:** $17.00 (6.4% risk)
- **Target:** $19.32 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 431
- **Position Value:** $7,826.96
- **Portfolio %:** 7.83%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-19 (Est: $0.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.60 | $0.69 | +15.4% |
| 2025Q2 | $0.61 | $0.54 | -11.5% |
| 2025Q1 | $0.48 | $0.55 | +13.8% |
| 2024Q4 | $0.53 | $0.58 | +9.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*